Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
June 13th, 2019
6.6K views
Here, we present a protocol to measure KDM1A target engagement in a human or animal cell, tissue or blood samples treated with KDM1A inhibitors. The protocol employs chemoprobe tagging of the free KDM1A enzyme and direct quantification of the target occupation using chemoprobe-based immunoassays and can be used in preclinical and clinical studies.
Overview
This article presents a protocol for measuring KDM1A target engagement in human or animal samples treated with KDM1A inhibitors. The method utilizes chemoprobe tagging and immunoassays for direct quantification of target occupation.
Key Study Components
Area of Science
- Neuroscience
- Pharmacology
- Drug Development
Background
- Target engagement is crucial for understanding drug efficacy.
- This technique allows direct measurement of KDM1A interactions.
- Applicable in both basic research and clinical trials.
- Focuses on oncological CNS diseases treated with KDM1A inhibitors.
Purpose of Study
- To assess the interaction of KDM1A inhibitors with their target.
- To measure dose effects and dynamics of KDM1A engagement.
- To provide a protocol for preclinical and clinical studies.
Methods Used
- Chemoprobe tagging of KDM1A enzyme.
- Direct quantification using chemoprobe-based immunoassays.
- Application of the method to various KDM1A inhibitors.
- Demonstration of the procedure by a lab operation manager.
Main Results
- Successful measurement of KDM1A target engagement.
- Demonstrated binding of ORY-1001 to KDM1A in cell treatments.
- Potential for use in pharmacodynamics studies.
- Protocol adaptable for other KDM1A inhibitors.
Conclusions
- This technique enhances the understanding of drug-target interactions.
- It provides a reliable method for assessing pharmacodynamics.
- Can be utilized in various research and clinical contexts.
Frequently Asked Questions
What is KDM1A?
KDM1A is a histone demethylase involved in gene regulation.
How does the chemoprobe work?
The chemoprobe tags the KDM1A enzyme, allowing for quantification of its engagement with inhibitors.
Can this method be used for other targets?
Yes, the strategy can be adapted for other protein targets beyond KDM1A.
What diseases can this technique be applied to?
It is applicable in oncological CNS diseases and potentially others treated with KDM1A inhibitors.
Who demonstrated the procedure?
The procedure was demonstrated by Raquel Ruiz, an operation manager in the PK/PD discovery platform.
What are the advantages of this technique?
It allows for direct measurement of drug-target interactions, providing insights into pharmacodynamics.
Executive Industry Relevance
Direct measurement of target engagement is critical for de-risking KDM1A inhibitor programs in oncology and CNS therapeutic areas. This chemoprobe-based immunoassay enables quantitative assessment of drug-target interaction without reliance on surrogate biomarkers, supporting go/no-go decisions in preclinical and clinical development. The method provides a scalable, species-agnostic approach to evaluate pharmacodynamics and inhibitor potency across diverse sample types.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypothesis by quantifying uninhibited KDM1A enzyme levels in native protein extracts.
- Operational Value: Supports functional target validation without genetic modification, applicable to cells or tissue samples from various species.
- Predictive Value: Facilitates dose-response analysis and dynamic monitoring of target engagement to inform lead optimization and portfolio triage.
Screening & Assay Development
- Assay Readiness: Generates standardized, quantitative readouts (RLU) from total and free KDM1A measurements to enable reliable compound evaluation.
- Reproducibility: Utilizes chemoprobe capture and immunoassay format with defined washing and incubation steps to ensure inter-assay consistency.
- Scalability: Compatible with 96-well plate formats and deep-well storage blocks for high-throughput screening of KDM1A inhibitors.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery and preclinical workflows by enabling target engagement assessment in both in vitro cell models and ex vivo tissue samples from dosed animals.
- Risk-Adjusted Advancement: Confirms target saturation in vivo, as demonstrated by lack of further engagement increase after four days of ORY-1001 treatment in rats.
- Biomarker Alignment: Provides direct target occupancy data that complements downstream pharmacodynamic markers like histone methylation or gene expression.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from early target validation through lead identification to preclinical pharmacodynamics studies, supporting iterative design of KDM1A inhibitors.
- Discovery Biology: Supports hypothesis testing by measuring direct compound binding to KDM1A, reducing reliance on indirect downstream effects.
- Screening: Enables assay-ready biological systems with quantitative outputs for comparing inhibitor potency and selectivity.
- Analytics: Generates normalized target engagement percentages via RLU-based standard curves, enabling cross-condition comparison and dose-response modeling.
- Translational Research: Connects in vitro findings to preclinical models through ex vivo analysis of tissue from dosed animals, confirming in vivo target inhibition.
- Enterprise Reuse: Represents a reusable platform capability applicable across multiple KDM1A inhibitor programs and adaptable to other targets via chemoprobe redesign.
Operational & Enterprise Impact
- Scientific Value: Delivers predictive confidence in target validation by providing direct, quantitative measurement of drug-target interaction.
- Operational Value: Ensures standardization and reproducibility through defined reagent concentrations, incubation times, and wash steps.
- Strategic Value: Improves go/no-go decision-making by reducing mechanistic ambiguity and late-stage biological risk in KDM1A inhibitor development.
- Portfolio Impact: Enables risk-adjusted prioritization based on confirmed target engagement across species and sample types.
Implementation Considerations
- Requires expertise in immunoassay techniques, protein extraction, and chemoprobe handling.
- Dependent on access to microplate readers, sonicators, centrifuges, and refrigerated storage for sample integrity.
- Necessitates cross-team standardization of lysis buffer preparation, chemoprobe titration, and ELISA protocol execution.
- Adaptation to new model systems requires validation of tissue homogenization and protein extraction efficiency.
- Practical limitations include the need for native protein preservation and avoidance of sample thawing during tissue processing.
Biopharma FAQs
Why does direct KDM1A target engagement measurement matter for target validation?
Direct measurement eliminates reliance on variable downstream biomarkers like histone marks or gene expression, which depend on cell type and genetic background. By quantifying uninhibited KDM1A via chemoprobe capture, the assay provides a consistent, mechanism-based readout of target occupancy. This supports more reliable target validation and hypothesis testing in drug discovery programs.
How does isolation of the free KDM1A variable fit into the discovery pipeline?
Isolating free (uninhibited) KDM1A allows precise quantification of target engagement by comparing it to total KDM1A levels in the same sample. This differential measurement enables calculation of the percentage of enzyme occupied by inhibitor across dose ranges. The approach fits into lead optimization by providing quantitative pharmacodynamics data to guide compound selection.
What quantitative dependent variable measurements does the assay enable?
The assay generates relative luminescence units (RLU) from chemoprobe-based ELISA, which are used to quantify free and total KDM1A protein levels. These RLU values are normalized against a standard curve to calculate target engagement percentages. The quantitative output supports dose-response modeling and cross-sample comparison in preclinical studies.
Why do replication requirements matter for cross-functional collaboration?
Replicate measurements ensure assay reliability and reproducibility across different operators, labs, and sample batches, which is essential for consistent data interpretation. Standardized washing, incubation, and detection steps minimize variability in signal generation. This consistency enables alignment between discovery, preclinical, and clinical teams on target engagement thresholds for go/no-go decisions.
What statistical analysis capabilities are required before implementing this assay?
Implementation requires the ability to generate standard curves from recombinant KDM1A to convert RLU values into absolute protein concentrations. Data analysis must include normalization of free and total KDM1A signals, calculation of target engagement percentages, and curve fitting for dose-response relationships. These capabilities are necessary to derive meaningful pharmacodynamics insights from raw luminescence readings.
